An innovative cancer therapy that saves animals can it help humans as well? - Cortisol Imbalances

Townsend Letter for Doctors and Patients, Feb-March, 2004 by Alfred J. Plechner

At six weeks the dog was retested. The levels had improved considerably. I switched the animal to 6-milligrams daily of oral Medrol.

Retesting after another two weeks showed further normalization.

The 52 pound female was examined, tested, and treated at the same time as the male. Her endocrine-immune levels were similarly abnormal. I injected her twice over a three-week period with 4-milligrams of Vetalog and 50-milligrams of Depomedrol, and prescribed .5 milligrams of T4 replacement twice daily. When her values normalized, I switched her to 4-milligrams of oral Medrol.

Both dogs have been maintained on this program since that time, are in good health, and happily involved in hunting activities.

When parents have similar imbalances, as these dogs did, experience has shown that the offspring will likely have the same abnormalities and a high risk of developing the same cancer.

The male and female Vizslas had been bred about one year before their operation. The mating produced six puppies. Shortly after treating the parents I tested these year-old puppies for imbalances (see Table 5). The litter comprised four males (54-60 pounds) and two females (50-56 pounds).

Each of the puppies, as Table 5 shows, had a similar imbalance pattern. The breeder agreed that the best preventive strategy was to normalize these imbalances with a proper hormone replacement program. Thus, the young dogs were placed on a combination of steroids (Medrol) and T4 medication, with dosages calculated according to their individual weight.

Four years later, the puppies and parents are still maintained on the program. No cancer has occurred during this time. The animals reside in different parts of the country and are under the care of other veterinarians who perform periodic blood tests.

Discussion and Implications for Humans

The testing and therapy program I have described here has produced outstanding results for many years in the treatment of many different types of cancer. I regard the outcomes as a successful strategy that identifies and corrects a causal adrenal defect that weakens and destabilizes the immune system.

The program can indeed extend the lives, and quality of living, of animal cancer patients if their physical condition has not been severely compromised by the disease. The earlier in the disease process that treatment begins the greater the potential for containment and recovery. The program will often prevent cancer from recurring or spreading.

Correcting the endocrine-immune defect restores impaired functions and often can prevent cancer in genetically predisposed animals. If not complete prevention, the program may at least keep the disease in check for many years.

Surgery, radiation, and chemotherapy are often indicated to eliminate tumors. The hormone replacement program is highly supportive, and, in fact, may ensure the success of those treatments. Conventional methods may not stop recurrence, but total containment may occur in association with the replacement therapy. Whether early or advanced cancer, repairing the defective endocrine-immune mechanism restores the patient's own powerful self-healing potential. Without this basic repair work, healing may never take place.